An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs. 2001;15(8):609–21.
Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38(3):191–204. doi: 10.2165/00003088-200038030-00001 .
Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45(11):1061–75. doi: 10.2165/00003088-200645110-00002 .
Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5–17.
Perucca E. Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res. 2002;52(1):25–33.
Verrotti A, Loiacono G, Ballone E, Mattei PA, Chiarelli F, Curatolo P. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol. 2011;44(5):347–9. doi: 10.1016/j.pediatrneurol.2010.12.005 .
Thompson AG, Cock HR. Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report. Seizure. 2016;39:1–4. doi: 10.1016/j.seizure.2016.04.003 .
Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49(7):1123–41. doi: 10.1111/j.1528-1167.2008.01665.x .
Gall Z, Vancea S, Szilagyi T, Gall O, Kolcsar M. Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats. Eur J Pharmaceut Sci. 2015;68:106–13. doi: 10.1016/j.ejps.2014.12.012 .
Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267–73. doi: 10.1007/s00228-007-0414-1 .
May TW, Boor R, Rambeck B, Jurgens U, Kon-Merker E, Brandt C. Serum concentrations of rufinamide in children and adults with epilepsy:the influence of dose, age and comedication. Ther Drug Monit. 2011;33(2):214–21. doi: 10.1097/FTD.0b013e31820fa9ad .
Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61(2):197–216.
Gall Z, Vancea S, Dogaru MT, Szilagyi T. Liquid chromatography-mass spectrometric determination of rufinamide in low volume plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;940:42–6. doi: 10.1016/j.jchromb.2013.07.014 .
la Marca G, Malvagia S, Filippi L, Innocenti M, Rosati A, Falchi M, et al. Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J Pharm Biomed Anal. 2011;54(1):192–7. doi: 10.1016/j.jpba.2010.07.015 .
Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin Pharmacother. 2016;. doi: 10.1517/14656566.2016.1161026 .
Verrotti A, Prezioso G, Stagi S, Paolino MC, Parisi P. Pharmacological considerations in the use of stiripentol for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2016;12(3):345–52. doi: 10.1517/17425255.2016.1145657 .
Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. Stiripentol. A novel antiepileptic drug. Pharmacol Rep. 2005;57(2):154–60.
Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23(11–12):523–33.
Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993;34(2):305–11.
May TW, Boor R, Mayer T, Jurgens U, Rambeck B, Holert N, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34(4):390–7. doi: 10.1097/FTD.0b013e31825dc4a6 .
Verdier MC, Tribut O, Bentue-Ferrer D. Therapeutic drug monitoring of stiripentol. Therapie. 2012;67(2):157–60. doi: 10.2515/therapie/2012014 .
Darwish HW, Abdelhameed AS, Attia MI. A stability-indicating HPLC-DAD method for determination of stiripentol: development, validation, kinetics, structure elucidation and application to commercial dosage form. J Anal Methods Chem. 2014;2014:638951. doi: 10.1155/2014/638951 .
French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology. 2015;85(11):950–7. doi: 10.1212/wnl.0000000000001930 .
Patsalos PN, Gougoulaki M, Sander JW. Perampanel serum concentrations in adults with epilepsy: effect of dose, age, gender and concomitant antiepileptic drugs. Ther Drug Monit. 2015;. doi: 10.1097/FTD.0000000000000274 .
Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19–24. doi: 10.1111/ane.12100 .
Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13–5. doi: 10.1111/epi.12504 .
Patsalos PN, Gougoulaki M, Sander JW. Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs. Ther Drug Monit. 2016;38(3):358–64. doi: 10.1097/ftd.0000000000000274 .
Baxter K, Sharp J. Orlistat and possible drug interactions that can affect over-the-counter sales. Pharmaceut J. 2010;284(7599):431.
Mano Y, Takenaka O, Kusano K. High-performance liquid chromatography-tandem mass spectrometry method for the determination of perampanel, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma. J Pharm Biomed Anal. 2015;107:56–62. doi: 10.1016/j.jpba.2014.12.018 .
Splinter MY. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Clin Ther. 2012;34(9):1845–56.e1. doi: 10.1016/j.clinthera.2012.07.009 .
Ihara Y, Tomonoh Y, Deshimaru M, Zhang B, Uchida T, Ishii A, et al. Retigabine, a Kv7.2/Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 Mutations. PLoS One. 2016;11(2):e0150095. doi: 10.1371/journal.pone.0150095 .
Plosker GL, Scott LJ. Retigabine: in partial seizures. CNS Drugs. 2006;20(7):601–8; discussion 9–10.
Lerche H, Daniluk J, Lotay N, DeRossett S, Edwards S, Brandt C. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Seizure. 2015;30:93–100. doi: 10.1016/j.seizure.2015.06.002 .
Knebel NG, Grieb S, Leisenheimer S, Locher M. Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;748(1):97–111.
Daniluk J, Cooper JA, Stender M, Kowalczyk A. Survey of physicians’ understanding of specific risks associated with retigabine. Drugs Real World Outcomes. 2016;3(2):155–63. doi: 10.1007/s40801-016-0068-3 .
Nass RD, Kurth C, Kull A, Graf W, Kasper B, Hamer HM, et al. Adjunctive retigabine in refractory focal epilepsy: postmarketing experience at four tertiary epilepsy care centers in Germany. Epilepsy Behav. 2016;56:54–8. doi: 10.1016/j.yebeh.2015.12.034 .
Douša M, Srbek J, Rádl S, Černý J, Klecán O, Havlíček J, et al. Identification, characterization, synthesis and HPLC quantification of new process-related impurities and degradation products in retigabine. J Pharm Biomed Anal. 2014;94:71–6. doi: 10.1016/j.jpba.2014.01.042 .
Shirley M, Dhillon S. Eslicarbazepine acetate monotherapy: a review in partial-onset seizures. Drugs. 2016;76(6):707–17. doi: 10.1007/s40265-016-0570-7 .
Poza-Aldea JJ. A proposal for a model to replace carbamazepine or oxcarbazepine by eslicarbazepine acetate in clinical practice. Rev Neurol. 2016;63(5):219–23.
Schmid E, Kuchukhidze G, Kirschner M, Leitinger M, Hofler J, Rohracher A, et al. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study. Acta Neurolog Scand. 2016;. doi: 10.1111/ane.12645 .
Ambrosio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol. 2001;61(10):1271–5.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83(1):1.
Johannessen Landmark C, Svendsen T, Dinarevic J, Kufaas RF, Reimers A, Brodtkorb E, et al. The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice. Ther Drug Monit. 2016;38(4):499–505. doi: 10.1097/ftd.0000000000000306 .
Maia J, Almeida L, Falcao A, Soares E, Mota F, Potgieter MA, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119–30.
Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45(9):1062–6. doi: 10.1177/0091270005279364 .
Rocamora R. A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. Ther Adv Neurolog Disord. 2015;8(4):178–86. doi: 10.1177/1756285615589711 .
Alves G, Fortuna A, Sousa J, Direito R, Almeida A, Rocha M, et al. Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites. Ther Drug Monit. 2010;32(4):512–6. doi: 10.1097/FTD.0b013e3181e5c855 .
Servais A-C, Janicot B, Takam A, Crommen J, Fillet M. Liquid chromatography separation of the chiral prodrug eslicarbazepine acetate and its main metabolites in polar organic mode. Application to their analysis after in vitro metabolism. J Chromatogr A. 2016;1467:306–11. doi: 10.1016/j.chroma.2016.07.022 .
Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):267–78. doi: 10.2165/00003088-199223040-00003 .
Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51(12):2423–31. doi: 10.1111/j.1528-1167.2010.02772.x .
Chang SY, Lin W-C. Determination of vigabatrin by capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;794(1):17–22. doi: 10.1016/S1570-0232(03)00396-9 .
Erdal J, Gram L, Alving J, Loscher W. Changes in plasma GABA concentration during vigabatrin treatment of epilepsy: a prospective study. Epilepsy Res. 1999;34(2–3):145–50.
Mueller SG, Weber OM, Duc CO, Weber B, Meier D, Russ W, et al. Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. Epilepsia. 2001;42(1):29–40.
Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003;25(4):457–62.
Kostic N, Dotsikas Y, Jovic N, Stevanovic G, Malenovic A, Medenica M. Vigabatrin in dried plasma spots: validation of a novel LC-MS/MS method and application to clinical practice. J Chromatogr B Anal Technol Biomed Life Sci. 2014;962:102–8. doi: 10.1016/j.jchromb.2014.05.037 .
Borrey DCR, Godderis KO, Engelrelst VIL, Bernard DR, Langlois MR. Quantitative determination of vigabatrin and gabapentin in human serum by gas chromatography–mass spectrometry. Clin Chim Acta. 2005;354(1–2):147–51. doi: 10.1016/j.cccn.2004.11.023 .
Chollet DF, Goumaz L, Juliano C, Anderegg G. Fast isocratic high-performance liquid chromatographic assay method for the simultaneous determination of gabapentin and vigabatrin in human serum. J Chromatogr B Biomed Sci Appl. 2000;746(2):311–4.
Martinc B, Roskar R, Grabnar I, Vovk T. Simultaneous determination of gabapentin, pregabalin, vigabatrin, and topiramate in plasma by HPLC with fluorescence detection. J Chromatogr B Anal Technol Biomed Life Sci. 2014;962:82–8. doi: 10.1016/j.jchromb.2014.05.030 .
Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother. 2010;11(9):1595–602. doi: 10.1517/14656566.2010.488639 .
Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother. 2012;13(5):699–715. doi: 10.1517/14656566.2012.667803 .
Alcantara-Montero A, Sanchez-Carnerero CI. Lacosamide and neuropathic pain, a review. Rev Neurol. 2016;62(5):223–9.
Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology. 2006;67(12 Suppl 4):S28–33.
Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50(4):459–71. doi: 10.1177/0091270009347675 .
Thomas D, Scharfenecker U, Schiltmeyer B, Doty P, Cawello W, Horstmann R. 640 Low potential for drug-drug-interaction of lacosamide. Eur J Pain. 2006;10(S1):S167c–8c. doi: 10.1016/S1090-3801(06)60643-5 .
Contin M, Albani F, Riva R, Candela C, Mohamed S, Baruzzi A. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013;35(6):849–52. doi: 10.1097/FTD.0b013e318290eacc .
Cawello W, Rosenkranz B, Schmid B, Wierich W. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54(3):530–6. doi: 10.1111/epi.12085 .
Sattler A, Schaefer M, May TW, Rambeck B, Brandt C. Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions–first clinical experience. Epilepsy Res. 2011;95(3):207–12. doi: 10.1016/j.eplepsyres.2011.03.019 .
Markoula S, Teotonio R, Ratnaraj N, Duncan JS, Sander JW, Patsalos PN. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit. 2014;36(4):494–8. doi: 10.1097/ftd.0000000000000051 .
Payto D, Foldvary-Schaefer N, So N, Bruton M, Wang S. A sensitive and rapid method for quantification of lacosamide and desmethyl lacosamide by LC-MS/MS. Bioanalysis. 2014;6(23):3161–8. doi: 10.4155/bio.14.158 .
Nikolaou P, Papoutsis I, Spiliopoulou C, Voudris C, Athanaselis S. A fully validated method for the determination of lacosamide in human plasma using gas chromatography with mass spectrometry: application for therapeutic drug monitoring. J Sep Sci. 2015;38(2):260–6. doi: 10.1002/jssc.201400858 .
Selak I. Pregabalin (Pfizer). Curr Opin Investig Drugs. 2001;2(6):828–34.
Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601–10. doi: 10.1185/03007995.2015.1134463 .
Raman S, DeAngelis C, Bruera E, Chow R, Lechner B, Chow E. Does pregabalin still have a role in treating cancer-induced bone pain? J Clin Oncol. 2016;34(6):524–6. doi: 10.1200/jco.2015.64.7545 .
Rajappa GC, Vig S, Bevanaguddaiah Y, Anadaswamy TC. Efficacy of pregabalin as premedication for post-operative analgesia in vaginal hysterectomy. Anesthesiol Pain Med. 2016;6(3):e34591. doi: 10.5812/aapm.34591 .
Sebastian B, Talikoti AT, Nelamangala K, Krishnamurthy D. Effect of oral pregabalin as preemptive analgesic in patients undergoing lower limb orthopedic surgeries under spinal anaesthesia. J Clin Diagn Res. 2016;10(7):UC01–UC4. doi: 10.7860/JCDR/2016/18854.8081 .
Otsuki T, Higuchi T, Yamazaki T, Okawa E, Okada K, Abe M. Efficacy and safety of pregabalin for the treatment of neuropathic pain in patients undergoing hemodialysis. Clin Drug Invest. 2016;. doi: 10.1007/s40261-016-0464-1 .
Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13–8. doi: 10.1111/j.0013-9580.2004.455003.x .
Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–83.
Haslam C, Nurmikko T. Pharmacological treatment of neuropathic pain in older persons. Clin Int Aging. 2008;3(1):111–20.
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76. doi: 10.1111/j.1528-1167.2008.01561.x .
May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29(6):789–94. doi: 10.1097/FTD.0b013e31815d0cd5 .
Winterfeld U, Merlob P, Baud D, Rousson V, Panchaud A, Rothuizen LE, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 2016;86(24):2251–7. doi: 10.1212/wnl.0000000000002767 .
Lavand’homme PM, Roelants F. Evaluation of pregabalin as an adjuvant to patient-controlled epidural analgesia during late termination of pregnancy. Anesthesiology. 2010;113(5):1186–91. doi: 10.1097/ALN.0b013e3181f5d32d .
Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit. 2005;27(4):451–6.
Kostic N, Dotsikas Y, Jovic N, Stevanovic G, Malenovic A, Medenica M. Quantitation of pregabalin in dried blood spots and dried plasma spots by validated LC-MS/MS methods. J Pharm Biomed Anal. 2015;109:79–84. doi: 10.1016/j.jpba.2015.02.023 .
Hlozek T, Bursova M, Coufal P, Cabala R. Gabapentin, pregabalin and vigabatrin quantification in human serum by GC-MS after hexyl chloroformate derivatization. J Anal Toxicol. 2016;. doi: 10.1093/jat/bkw070 .
Yoshikawa N, Naito T, Yagi T, Kawakami J. A validated fluorometric method for the rapid determination of pregabalin in human plasma applied to patients with pain. Ther Drug Monit. 2016;38(5):628–33. doi: 10.1097/ftd.0000000000000325 .
Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol Bull. 2011;44(1):5–17.
Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26(10):1199–202. doi: 10.1111/j.1468-2982.2006.01191.x .
Hainque E, Vidailhet M, Cozic N, Charbonnier-Beaupel F, Thobois S, Tranchant C, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016;86(18):1729–35. doi: 10.1212/wnl.0000000000002631 .
Hamer H, Baulac M, McMurray R, Kockelmann E. Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: results of the observational study ZOOM. Seizure. 2016;34:66–73. doi: 10.1016/j.seizure.2015.12.001 .
Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996;31(1):29–46. doi: 10.2165/00003088-199631010-00003 .
Ijiri Y, Inoue T, Fukuda F, Suzuki K, Kobayashi T, Shibahara N, et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia. 2004;45(8):924–7. doi: 10.1111/j.0013-9580.2004.30603.x .
Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45(4):351–63. doi: 10.2165/00003088-200645040-00002 .
Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit. 1998;20(6):593–7.
Antonilli L, Brusadin V, Filipponi F, Guglielmi R, Nencini P. Development and validation of an analytical method based on high performance thin layer chromatography for the simultaneous determination of lamotrigine, zonisamide and levetiracetam in human plasma. J Pharm Biomed Anal. 2011;56(4):763–70. doi: 10.1016/j.jpba.2011.07.018 .
Subramanian M, Birnbaum AK, Remmel RP. High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit. 2008;30(3):347–56. doi: 10.1097/FTD.0b013e3181678ecb .
Shimoyama R, Ohkubo T, Sugawara K. Monitoring of zonisamide in human breast milk and maternal plasma by solid-phase extraction HPLC method. Biomed Chromatogr. 1999;13(5):370–2.
Ito S, Yano I, Hashi S, Tsuda M, Sugimoto M, Yonezawa A, et al. Population pharmacokinetic modeling of levetiracetam in pediatric and adult patients with epilepsy by using routinely monitored data. Ther Drug Monit. 2016;. doi: 10.1097/FTD.0000000000000291 .
Patanwala AE, Kurita A, Truong E. Low-dose levetiracetam for seizure prophylaxis after traumatic brain injury. Brain Inj. 2016;30(2):156–8. doi: 10.3109/02699052.2015.1089596 .
Johannessen Landmark C, Baftiu A, Tysse I, Valso B, Larsson PG, Rytter E, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit. 2012;34(4):440–5. doi: 10.1097/FTD.0b013e31825ee389 .
Sheinberg R, Heyman E, Dagan Z, Youngster I, Kohn E, Gandelman-Marton R, et al. Correlation between efficacy of levetiracetam and serum levels among children with refractory epilepsy. Pediatr Neurol. 2015;52(6):624–8. doi: 10.1016/j.pediatrneurol.2015.01.012 .
Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77–85.
Tomson T, Palm R, Kallen K, Ben-Menachem E, Soderfeldt B, Danielsson B, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111–6. doi: 10.1111/j.1528-1167.2007.01032.x .
Martinez Ferri M, Pena Mayor P, Perez Lopez-Fraile I, Escartin Siquier A, Martin Moro M, Forcadas Berdusan M. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. Neurologia. 2016;. doi: 10.1016/j.nrl.2016.05.004 .
Pucci V, Bugamelli F, Mandrioli R, Ferranti A, Kenndler E, Raggi MA. High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed Chromatogr. 2004;18(1):37–44. doi: 10.1002/bmc.289 .
Vermeij TAC, Edelbroek PM. High-performance liquid chromatographic and megabore gas–liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction. J Chromatogr B Biomed Appl. 1994;662(1):134–9.
Gustavson LE, Boellner SW, Granneman GR, Qian JX, Guenther HJ, el-Shourbagy T, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology. 1997;48(4):1032–7.
Uthman BM, Rowan AJ, Ahmann PA, Leppik IE, Schachter SC, Sommerville KW, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol. 1998;55(1):56–62.
Wang X, PATSALOS PN. The pharmacokinetic profile of tiagabine. Rev Contemp Pharmacother. 2002;12(5):225–33.
Lau AH, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia. 1997;38(4):445–51.
Mozayani A, Carter J, Nix R. Distribution of topiramate in a medical examiner’s case. J Anal Toxicol. 1999;23(6):556–8.
Bahrami G, Mirzaeei S, Kiani A. Sensitive analytical method for Topiramate in human serum by HPLC with pre-column fluorescent derivatization and its application in human pharmacokinetic studies. J Chromatogr B Anal Technolog Biomed Life Sci. 2004;813(1–2):175–80. doi: 10.1016/j.jchromb.2004.09.054 .
Vinton A, Kornberg AJ, Cowley M, Matkovic Z, Kilpatrick C, O’Brien TJ. Tiagabine-induced generalised non convulsive status epilepticus in patients with lesional focal epilepsy. J Clin Neurosci. 2005;12(2):128–33. doi: 10.1016/j.jocn.2004.03.027 .
Williams J, Bialer M, Johannessen SI, Kramer G, Levy R, Mattson RH, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia. 2003;44(1):40–5.
Gustavson LE, Chu SY. High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr. 1992;574(2):313–8.
Wang X, Ratnaraj N, Patsalos PN. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure. 2004;13(8):574–81. doi: 10.1016/j.seizure.2004.01.007 .
Chollet DF, Castella E, Goumaz L, Anderegg G. Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine. J Pharm Biomed Anal. 1999;21(3):641–6.
Motaghinejad M, Motevalian M, Shabab B. Neuroprotective effects of various doses of topiramate against methylphenidate induced oxidative stress and inflammation in rat isolated hippocampus. Clin Exp Pharmacol Physiol. 2016;43(3):360–71. doi: 10.1111/1440-1681.12538 .
LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA. 2004;291(5):615–20. doi: 10.1001/jama.291.5.615 .
Ferrari AR, Guerrini R, Gatti G, Alessandri MG, Bonanni P, Perucca E. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit. 2003;25(6):700–8.
May TW, Brandt C, Helmer R, Bien CG, Cawello W. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy. Epilepsia. 2015;56(7):1134–40. doi: 10.1111/epi.13022 .
Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol. 1996;36(10):884–91.
Froscher W, Schier KR, Hoffmann M, Meyer A, May TW, Rambeck B, et al. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord. 2005;7(3):237–48.
Ohman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res. 2009;87(2–3):124–9. doi: 10.1016/j.eplepsyres.2009.08.004 .
Penovich PE, Schroeder M, Gates JR, Morriatry GL. Clinical experience with topiramate: correlation of serum levels with efficacy and adverse effects. Epilepsia. 1997;38(8):181.
Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia. 2000;41(3):338–41.
Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25(3):347–63.
Brandt C, Elsner H, Furatsch N, Hoppe M, Nieder E, Rambeck B, et al. Topiramate overdose: a case report of a patient with extremely high topiramate serum concentrations and nonconvulsive status epilepticus. Epilepsia. 2010;51(6):1090–3. doi: 10.1111/j.1528-1167.2009.02395.x .
Miles MV, Tang PH, Glauser TA, Ryan MA, Grim SA, Strawsburg RH, et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol. 2003;29(2):143–7.
Berry DJ, Patsalos PN. Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. Ther Drug Monit. 2000;22(4):460–4.
Tang PH, Miles MV, Glauser TA, Coletta L, Doughman N, Doose D, et al. An improved gas chromatography assay for topiramate monitoring in pediatric patients. Ther Drug Monit. 2000;22(2):195–201.
Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit. 2003;25(3):314–22.
Snozek CL, Rollins LA, Peterson PW, Langman LJ. Comparison of a new serum topiramate immunoassay to fluorescence polarization immunoassay. Ther Drug Monit. 2010;32(1):107–11. doi: 10.1097/FTD.0b013e3181c4cebb .
Carlow DC, Shi H, Schofield RC. Simultaneous quantitation of lamotrigine, levetiracetam, 10-hydroxycarbazepine, topiramate, and zonisamide in serum using HPLC-MS/MS. Methods Mol Biol. 2016;1383:29–37. doi: 10.1007/978-1-4939-3252-8_4 .
Yasumoto S, Shimizu M, Sato K, Kurata A, Numachi Y. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: a multi-center, uncontrolled, open-label study. Brain Dev. 2016;38(4):407–13. doi: 10.1016/j.braindev.2015.10.007 .
Warshavsky A, Eilam A, Gilad R. Lamotrigine as monotherapy in clinical practice: efficacy of various dosages in epilepsy. Brain Behav. 2016;6(3):e00419. doi: 10.1002/brb3.419 .
Nakamura A, Mihara K, Nagai G, Kagawa S, Suzuki T, Nemoto K, et al. Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma lamotrigine concentration at week 2. Ther Drug Monit. 2016;38(3):379–82. doi: 10.1097/ftd.0000000000000279 .
Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48(3):484–9. doi: 10.1111/j.1528-1167.2007.00997.x .
Tomson T, Luef G, Sabers A, Pittschieler S, Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology. 2006;67(7):1297–9. doi: 10.1212/01.wnl.0000238522.79277.9c .
Paul F, Veauthier C, Fritz G, Lehmann TN, Aktas O, Zipp F, et al. Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. Seizure. 2007;16(6):479–84. doi: 10.1016/j.seizure.2007.03.006 .
Sondergaard Khinchi M, Nielsen KA, Dahl M, Wolf P. Lamotrigine therapeutic thresholds. Seizure. 2008;17(5):391–5. doi: 10.1016/j.seizure.2007.11.023 .
Kaufman KR. Lamotrigine and hemodialysis in bipolar disorder: case analysis of dosing strategy with literature review. Bipolar Disord. 2010;12(4):446–9. doi: 10.1111/j.1399-5618.2010.00818.x .
Marcellin P, de Bony F, Garret C, Altman C, Boige V, Castelnau C, et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol. 2001;51(5):410–4.
Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol. 2006;2(6):1009–18. doi: 10.1517/17425255.2.6.1009 .
Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs. 1995;50(4):691–713.
May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 1999;21(2):175–81.
Pennell PB, Hovinga CA. Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics. Int Rev Neurobiol. 2008;83:227–40. doi: 10.1016/S0074-7742(08)00013-5 .
Paulzen M, Lammertz SE, Veselinovic T, Goecke TW, Hiemke C, Grunder G. Lamotrigine in pregnancy—therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol. 2015;30(5):249–54. doi: 10.1097/yic.0000000000000088 .
Croci D, Salmaggi A, de Grazia U, Bernardi G. New high-performance liquid chromatographic method for plasma/serum analysis of lamotrigine. Ther Drug Monit. 2001;23(6):665–8.
Morgan PE, Fisher DS, Evers R, Flanagan RJ. A rapid and simple assay for lamotrigine in serum/plasma by HPLC, and comparison with an immunoassay. Biomed Chromatogr. 2011;25(7):775–8. doi: 10.1002/bmc.1515 .
Westley IS, Morris RG. Seradyn quantitative microsphere system lamotrigine immunoassay on a Hitachi 911 analyzer compared with HPLC-UV. Ther Drug Monit. 2008;30(5):634–7. doi: 10.1097/FTD.0b013e31818580b3 .
Dasgupta A, Hart AP. Lamotrigine analysis in plasma by gas chromatography–mass spectrometry after conversion to a tert.-butyldimethylsilyl derivative. J Chromatogr B Biomed Sci Appl. 1997;693(1):101–7. doi: 10.1016/S0378-4347(97)00064-9 .
Wyszomirska E, Czerwinska K. Identification and assay of lamotrigine in human milk with gas chromatography and densitometry. Acta Pol Pharm. 1999;56(2):101–5.
van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6):1001–19.
Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit. 1997;19(1):29–36.
Glue P, Sulowicz W, Colucci R, Banfield C, Pai S, Lin C, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol. 1997;44(1):91–3.
Troupin AS, Montoris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy. 1997;10(1):26–31. doi: 10.1016/S0896-6974(96)00063-1 .
Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia. 1996;37(3):280–3.
Contin M, Balboni M, Callegati E, Candela C, Albani F, Riva R, et al. Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J Chromatogr, B: Anal Technol Biomed Life Sci. 2005;828(1–2):113–7. doi: 10.1016/j.jchromb.2005.09.009 .
Rifai N, Fuller D, Law T, Mikati M. Measurement of felbamate by wide-bore capillary gas chromatography and flame ionization detection. Clin Chem. 1994;40(5):745–8.
Tang PH. Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection. J Anal Toxicol. 2008;32(5):373–8.
Thompson CD, Barthen MT, Hopper DW, Miller TA, Quigg M, Hudspeth C, et al. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia. 1999;40(6):769–76.
Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Invest. 2013;33(6):401–8. doi: 10.1007/s40261-013-0080-2 .
Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986;36(5):830–9.
Petroff OA, Hyder F, Rothman DL, Mattson RH. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia. 2000;41(6):675–80.
Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharmaceut Res. 1993;10(2):276–81.
McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia. 1999;40(Suppl 6):S39–50 (discussion S73–4).
Armijo JA, Pena MA, Adin J, Vega-Gil N. Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis. Therap Drug Monitor. 2004;26(6):633–7.
McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44(6 Suppl 5):S17–22 (discussion S31–2).
Ifa DR, Falci M, Moraes ME, Bezerra FA, Moraes MO, de Nucci G. Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J Mass Spectrometr. 2001;36(2):188–94. doi: 10.1002/jms.120 .
Ikeda K, Ikawa K, Yokoshige S, Yoshikawa S, Morikawa N. Gas chromatography-electron ionization-mass spectrometry quantitation of valproic acid and gabapentin, using dried plasma spots, for therapeutic drug monitoring in in-home medical care. Biomed Chromatogr. 2014;28(12):1756–62. doi: 10.1002/bmc.3217 .